Диссертация (1140892), страница 24
Текст из файла (страница 24)
157, № 3. ‒ C. 215-25.150. Carter M. C., Metcalfe D. D., Komarow H. D. Mastocytosis // Immunol Allergy Clin North Am.‒ 2014. ‒ T. 34, № 1. ‒ C. 181-96.151. Castells M., Austen K. F. Mastocytosis: mediator-related signs and symptoms // Int Arch AllergyImmunol. ‒ 2002. ‒ T. 127, № 2. ‒ C. 147-52.152. Shim W. S., Oh U. Histamine-induced itch and its relationship with pain // Mol Pain. ‒ 2008. ‒ T.4.
‒ C. 29.153. Yang L., Murota H., Serada S., Fujimoto M., Kudo A., Naka T., Katayama I. Histaminecontributes to tissue remodeling via periostin expression // J Invest Dermatol. ‒ 2014. ‒ T. 134,№ 8. ‒ C. 2105-2113.154. Castells M. Mast cell mediators in allergic inflammation and mastocytosis // Immunol AllergyClin North Am. ‒ 2006. ‒ T. 26, № 3.
‒ C. 465-85.155. Hannah-Shmouni F., Stratakis C. A., Koch C. A. Flushing in (neuro)endocrinology // Rev EndocrMetab Disord. ‒ 2016. ‒ T. 17, № 3. ‒ C. 373-380.141156. Sukrithan V. K., Salamon J. N., Berulava G., Sibinga N. E., Verma A. Systemic mastocytosispresenting as cardiac tamponade with CD25(+) pericardial mast cells // Clin Case Rep. ‒ 2016.‒ T.
4, № 3. ‒ C. 279-81.157. Rossini M., Zanotti R., Viapiana O., Tripi G., Orsolini G., Idolazzi L., Bonadonna P., Schena D.,Escribano L., Adami S., Gatti D. Bone involvement and osteoporosis in mastocytosis //Immunol Allergy Clin North Am. ‒ 2014. ‒ T. 34, № 2. ‒ C. 383-96.158. Escribano L., Alvarez-Twose I., Sanchez-Munoz L., Garcia-Montero A., Nunez R., Almeida J.,Jara-Acevedo M., Teodosio C., Garcia-Cosio M., Bellas C., Orfao A. Prognosis in adultindolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis ina series of 145 patients // J Allergy Clin Immunol. ‒ 2009.
‒ T. 124, № 3. ‒ C. 514-21.159. Maeda H., Yamagata A., Nishikawa S., Yoshinaga K., Kobayashi S., Nishi K. Requirement of ckit for development of intestinal pacemaker system // Development. ‒ 1992. ‒ T. 116, № 2. ‒C. 369-75.160. Huizinga J. D., Thuneberg L., Kluppel M., Malysz J., Mikkelsen H.
B., Bernstein A. W/kit generequired for interstitial cells of Cajal and for intestinal pacemaker activity // Nature. ‒ 1995. ‒T. 373, № 6512. ‒ C. 347-9.161. Thomas I., Kihiczak G. G., Fox M. D., Janniger C. K., Schwartz R. A. Piebaldism: an update //Int J Dermatol. ‒ 2004. ‒ T. 43, № 10. ‒ C. 716-9.162. Matito A., Alvarez-Twose I., Morgado J. M., Sanchez-Munoz L., Orfao A., Escribano L.Anaphylaxis as a clinical manifestation of clonal mast cell disorders // Curr Allergy AsthmaRep. ‒ 2014. ‒ T.
14, № 8. ‒ C. 450.163. Bonadonna P., Perbellini O., Passalacqua G., Caruso B., Colarossi S., Dal Fior D., Castellani L.,Bonetto C., Frattini F., Dama A., Martinelli G., Chilosi M., Senna G., Pizzolo G., Zanotti R.Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings andincreased serum tryptase levels // J Allergy Clin Immunol. ‒ 2009.
‒ T. 123, № 3. ‒ C. 680-6.164. Alvarez-Twose I., Gonzalez de Olano D., Sanchez-Munoz L., Matito A., Esteban-Lopez M. I.,Vega A., Mateo M. B., Alonso Diaz de Durana M. D., de la Hoz B., Del Pozo Gil M. D.,Caballero T., Rosado A., Sanchez Matas I., Teodosio C., Jara-Acevedo M., Mollejo M.,Garcia-Montero A., Orfao A., Escribano L. Clinical, biological, and molecular characteristicsof clonal mast cell disorders presenting with systemic mast cell activation symptoms // JAllergy Clin Immunol.
‒ 2010. ‒ T. 125, № 6. ‒ C. 1269-1278 e2.165. Brockow K., Metcalfe D. D. Mastocytosis // Chem Immunol Allergy. ‒ 2010. ‒ T. 95. ‒ C. 11024.142166. Akin C., Valent P., Metcalfe D. D. Mast cell activation syndrome: Proposed diagnostic criteria //J Allergy Clin Immunol. ‒ 2010. ‒ T. 126, № 6. ‒ C. 1099-104 e4.167. Wimazal F., Geissler P., Shnawa P., Sperr W. R., Valent P.
Severe life-threatening or disablinganaphylaxis in patients with systemic mastocytosis: a single-center experience // Int ArchAllergy Immunol. ‒ 2012. ‒ T. 157, № 4. ‒ C. 399-405.168. van der Veer E., van der Goot W., de Monchy J. G., Kluin-Nelemans H. C., van Doormaal J. J.High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis// Allergy.
‒ 2012. ‒ T. 67, № 3. ‒ C. 431-8.169. Pardanani A. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, andmanagement // Am J Hematol. ‒ 2015. ‒ T. 90, № 3. ‒ C. 250-62.170. Теплюк Н.П. П. П. М., . Качество жизни и уровень депрессии у больных мастоцитозом //РМЖ. Медицинское обозрение. ‒ 2018.
№ № 4. . ‒ C. С. 40-42.171. Moura D. S., Sultan S., Georgin-Lavialle S., Pillet N., Montestruc F., Gineste P., Barete S.,Damaj G., Moussy A., Lortholary O., Hermine O. Depression in patients with mastocytosis:prevalence, features and effects of masitinib therapy // PLoS One. ‒ 2011. ‒ T. 6, № 10.
‒ C.e26375.172. Georgin-Lavialle S., Moura D. S., Salvador A., Chauvet-Gelinier J. C., Launay J. M., Damaj G.,Cote F., Soucie E., Chandesris M. O., Barete S., Grandpeix-Guyodo C., Bachmeyer C.,Alyanakian M. A., Aouba A., Lortholary O., Dubreuil P., Teyssier J. R., Trojak B., Haffen E.,Vandel P., Bonin B., Hermine O., Gaillard R.
Mast cells' involvement in inflammationpathways linked to depression: evidence in mastocytosis // Mol Psychiatry. ‒ 2016. ‒ T. 21, №11. ‒ C. 1511-1516.173. Silver R., Curley J. P. Mast cells on the mind: new insights and opportunities // Trends Neurosci.‒ 2013. ‒ T. 36, № 9. ‒ C. 513-21.174. Campbell D. J., Kernan J. A. Mast cells in the central nervous system // Nature. ‒ 1966. ‒ T. 210,№ 5037. ‒ C. 756-7.175. Cirulli F., Pistillo L., de Acetis L., Alleva E., Aloe L.
Increased number of mast cells in thecentral nervous system of adult male mice following chronic subordination stress // BrainBehav Immun. ‒ 1998. ‒ T. 12, № 2. ‒ C. 123-33.176. Nautiyal K. M., Ribeiro A. C., Pfaff D. W., Silver R. Brain mast cells link the immune system toanxiety-like behavior // Proc Natl Acad Sci U S A.
‒ 2008. ‒ T. 105, № 46. ‒ C. 18053-7.177. Theoharides T. C. Mast cells and stress--a psychoneuroimmunological perspective // J ClinPsychopharmacol. ‒ 2002. ‒ T. 22, № 2. ‒ C. 103-8.143178. Frenzel L., Hermine O. Mast cells and inflammation // Joint Bone Spine. ‒ 2013. ‒ T. 80, № 2. ‒C. 141-5.179. Kawasaki H., Chang H. W., Tseng H.
C., Hsu S. C., Yang S. J., Hung C. H., Zhou Y., Huang S.K. A tryptophan metabolite, kynurenine, promotes mast cell activation through arylhydrocarbon receptor // Allergy. ‒ 2014. ‒ T. 69, № 4. ‒ C. 445-52.180. Zhou Y., Tung H. Y., Tsai Y. M., Hsu S. C., Chang H.
W., Kawasaki H., Tseng H. C., PlunkettB., Gao P., Hung C. H., Vonakis B. M., Huang S. K. Aryl hydrocarbon receptor controlsmurine mast cell homeostasis // Blood. ‒ 2013. ‒ T. 121, № 16. ‒ C. 3195-204.181. Sibilano R., Frossi B., Calvaruso M., Danelli L., Betto E., Dall'Agnese A., Tripodo C., ColomboM. P., Pucillo C. E., Gri G.
The aryl hydrocarbon receptor modulates acute and late mast cellresponses // J Immunol. ‒ 2012. ‒ T. 189, № 1. ‒ C. 120-7.182. Kushnir-Sukhov N. M., Brittain E., Scott L., Metcalfe D. D. Clinical correlates of blood serotoninlevels in patients with mastocytosis // Eur J Clin Invest. ‒ 2008. ‒ T. 38, № 12. ‒ C.
953-8.183. Williams K. W., Metcalfe D. D., Prussin C., Carter M. C., Komarow H. D. Telangiectasiamacularis eruptiva perstans or highly vascularized urticaria pigmentosa? // J Allergy ClinImmunol Pract. ‒ 2014. ‒ T. 2, № 6. ‒ C. 813-5.184. Brockow K., Akin C., Huber M., Metcalfe D. D. Assessment of the extent of cutaneousinvolvement in children and adults with mastocytosis: relationship to symptomatology,tryptase levels, and bone marrow pathology // J Am Acad Dermatol. ‒ 2003. ‒ T. 48, № 4.
‒ C.508-16.185. Galen B. T., Rose M. G. Darier's sign in mastocytosis // Blood. ‒ 2014. ‒ T. 123, № 8. ‒ C. 1127.186. Skrabs C. C. Darier sign: a historical note // Arch Dermatol. ‒ 2002. ‒ T. 138, № 9. ‒ C. 1253-4.187. Lange M., Niedoszytko M., Nedoszytko B., Lata J., Trzeciak M., Biernat W. Diffuse cutaneousmastocytosis: analysis of 10 cases and a brief review of the literature // J Eur Acad DermatolVenereol. ‒ 2012. ‒ T. 26, № 12. ‒ C. 1565-71.188. Neri I., Virdi A., Balestri R., Patrizi A.
Diffuse cutaneous mastocytosis: a heterogeneous disease// Arch Dis Child. ‒ 2013. ‒ T. 98, № 8. ‒ C. 607.189. Wawrzycki B., Pietrzak A., Chodorowska G., Kanitakis J. Diffuse cutaneous bullousmastocytosis in a newborn // Dermatol Ther. ‒ 2013. ‒ T. 26, № 2. ‒ C. 176-9.190. Horny H. P., Valent P. Diagnosis of mastocytosis: general histopathological aspects,morphological criteria, and immunohistochemical findings // Leuk Res. ‒ 2001.
‒ T. 25, № 7.‒ C. 543-51.191. Escribano L., Akin C., Castells M., Orfao A., Metcalfe D. D. Mastocytosis: current concepts indiagnosis and treatment // Ann Hematol. ‒ 2002. ‒ T. 81, № 12. ‒ C. 677-90.144192. Valent P., Sperr W. R., Schwartz L. B., Horny H. P. Diagnosis and classification of mast cellproliferative disorders: delineation from immunologic diseases and non-mast cellhematopoietic neoplasms // J Allergy Clin Immunol.
‒ 2004. ‒ T. 114, № 1. ‒ C. 3-11; quiz 12.193. Horny H. P., Sotlar K., Valent P. Mastocytosis: state of the art // Pathobiology. ‒ 2007. ‒ T. 74,№ 2. ‒ C. 121-32.194. Valent P., Akin C., Sperr W. R., Horny H. P., Metcalfe D. D. Mast cell proliferative disorders:current view on variants recognized by the World Health Organization // Hematol Oncol ClinNorth Am. ‒ 2003. ‒ T. 17, № 5. ‒ C. 1227-41.195. Valent P., Akin C., Sperr W. R., Escribano L., Arock M., Horny H. P., Bennett J. M., Metcalfe D.D.
Aggressive systemic mastocytosis and related mast cell disorders: current treatment optionsand proposed response criteria // Leuk Res. ‒ 2003. ‒ T. 27, № 7. ‒ C. 635-41.196. Pardanani A., Lim K. H., Lasho T. L., Finke C. M., McClure R. F., Li C. Y., Tefferi A. WHOsubvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159consecutive adults // Blood. ‒ 2010. ‒ T.
115, № 1. ‒ C. 150-1.197. Matito A., Morgado J. M., Alvarez-Twose I., Sanchez-Munoz L., Pedreira C. E., Jara-AcevedoM., Teodosio C., Sanchez-Lopez P., Fernandez-Nunez E., Moreno-Borque R., Garcia-MonteroA., Orfao A., Escribano L. Serum tryptase monitoring in indolent systemic mastocytosis:association with disease features and patient outcome // PLoS One. ‒ 2013. ‒ T.
8, № 10. ‒ C.e76116.198. Jawhar M., Schwaab J., Hausmann D., Clemens J., Naumann N., Henzler T., Horny H. P., SotlarK., Schoenberg S. O., Cross N. C., Fabarius A., Hofmann W. K., Valent P., Metzgeroth G.,ReiterA.Splenomegaly,elevatedalkalinephosphataseandmutationsintheSRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients withsystemic mastocytosis // Leukemia.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
